None listed
Conditions
Brief summary
This is a pilot feasibility trial of freeze-dried plasma vs standard therapy for patients with haemorrhagic shock receiving pre-hospital blood (Population). This will be an open label, randomised controlled trial. The Intervention will be freeze-dried plasma, obtained for the trial from the German Red Cross (LyoPlas N-w). The Comparator will be standard care, which in the Australian context is no plasma or other clotting factor replacement. The primary Outcome will be feasibility of implementation, measured by the proportion of randomised patients who complete the intervention. Secondary outcomes, assessed for possible use as primary outcomes in any subsequent definitive trial, will include mortality at 24 hours and at hospital discharge, coagulation status on arrival to hospital, and total blood product use within 24 hours of hospital arrival.
Interventions
Sponsors
Study design
Eligibility
Inclusion criteria
1. Adult patients (age greater than or equal to 18 years); 2. Injured through any mechanism; 3. Patients to be transported to a participating trauma centre (The Alfred). 4. Receiving any pre-hospital red cells as per Ambulance Victoria AAV Clinical Practice Guidelines o The transfusion of red cells by HEMS paramedics was implemented in Victoria in April 2011. Primary emergency indication for the administration of red cells is evidence of shock (hypotension and/or tachycardia) following trauma. 5. Able to receive two units of pre-hospital freeze-dried plasma
Exclusion criteria
Extremes of age (>90 years or <18 years) 2. No intravenous access 3. Known pregnancy 4. Palliative care